Copper(II) complexes with antimicrobial drug flumequine: Structure and biological evaluation

Different types of copper complexes with the quinolone antimicrobial drugs ofloxacin and norfloxacin: Structure, DNA- and albumin-binding

“…In conclusion, the association binding constants K of all complexes for both albumins exhibit values in the range 1.73×10 4 -7.20×10 5 M −1 ( Table 6) and are lower than that of the avidin-ligands binding affinity (K avidin-ligands ≈10 15 M −1 ) which is among the highest observed [44]; the existing data for the quinolones and complexes 1-4 show that they can bind on the albumin and have simultaneously the potential to get released from the albumins upon arrival at the target cells. Therefore, the interaction of compounds with albumins may provide useful information concerning any potential application.…”

“…The interaction of copper(II) with diverse quinolone ligands have been thoroughly studied. In the literature, the structures and study of (i) binary copper(II) complexes of ciprofloxacin [33,34], cinoxacin [35,36] and sparfloxacin [37], (ii) mixed-ligands mononuclear copper(II) complexes with cinoxacin [38,39], ciprofloxacin [40][41][42], enrofloxacin [43], flumequine [44], nalidixic acid [45], norfloxacin [21], ofloxacin [4], oxolinic acid [46], pipemidic acid [47], N-propyl-norfloxacin [28,48] and sparfloxacin [49,50] as well as (iii) the ionic copper(II) complexes of protonated norfloxacin [21,51] have been reported.…”

Structure, antimicrobial activity, DNA- and albumin-binding of manganese(II) complexes with the quinolone antimicrobial agents oxolinic acid and enrofloxacin

“…In conclusion, the K values of the complexes for both albumins, being in the range of 1.82× 10 4 -5.63× 10 5 M −1 ( Table 6), show that the complexes can bind on the albumin and have simultaneously the potential to get released from the albumins upon arrival at the target cells; the K values are lower than that of the avidin-ligand binding affinity (K avidin-ligands ≈ 10 15 M − 1 ) which is among the highest observed [80]. Therefore, the study of the binding to albumins may reveal useful information concerning future application.…”

A mononuclear Cu(II) complex with 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine: Synthesis, crystal structure, DNA- and BSA-binding, molecular modeling, and anticancer activity against MCF-7, A-549, and HT-29 cell lines

“…A C C E P T E D ACCEPTED MANUSCRIPT 4 decades, and these complexes are still an important target of research in bioinorganic and medicinal chemistry [17,18]. A variety of Cu(II) complexes have been studied as potential anticancer drugs, and many of them show remarkable cytotoxicity activity [19][20][21].…”